DK1578772T3 - Cytokiner og cytokinreceptorer med reduceret immunogenicitet - Google Patents

Cytokiner og cytokinreceptorer med reduceret immunogenicitet

Info

Publication number
DK1578772T3
DK1578772T3 DK03713721.3T DK03713721T DK1578772T3 DK 1578772 T3 DK1578772 T3 DK 1578772T3 DK 03713721 T DK03713721 T DK 03713721T DK 1578772 T3 DK1578772 T3 DK 1578772T3
Authority
DK
Denmark
Prior art keywords
cytokines
cytokine receptors
reduced immunogenicity
present
receptors
Prior art date
Application number
DK03713721.3T
Other languages
English (en)
Inventor
Fiona A Harding
Scott D Power
Original Assignee
Danisco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco Us Inc filed Critical Danisco Us Inc
Application granted granted Critical
Publication of DK1578772T3 publication Critical patent/DK1578772T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Color Television Image Signal Generators (AREA)
DK03713721.3T 2002-05-01 2003-02-26 Cytokiner og cytokinreceptorer med reduceret immunogenicitet DK1578772T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37674302P 2002-05-01 2002-05-01
PCT/US2003/005917 WO2003104263A2 (en) 2002-05-01 2003-02-26 Cytokines and cytokine receptors with reduced immunogenicity

Publications (1)

Publication Number Publication Date
DK1578772T3 true DK1578772T3 (da) 2010-08-16

Family

ID=29736065

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03713721.3T DK1578772T3 (da) 2002-05-01 2003-02-26 Cytokiner og cytokinreceptorer med reduceret immunogenicitet

Country Status (7)

Country Link
US (3) US20050220800A1 (da)
EP (1) EP1578772B1 (da)
AT (1) ATE467421T1 (da)
AU (1) AU2003217758A1 (da)
DE (1) DE60332556D1 (da)
DK (1) DK1578772T3 (da)
WO (1) WO2003104263A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184519A1 (en) * 2003-04-02 2007-08-09 Shabnam Tangri Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
WO2004113387A2 (en) * 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
ATE368687T1 (de) * 2003-06-26 2007-08-15 Merck Patent Gmbh Thrombopoietinproteine mit verbesserten eigenschaften
KR100632985B1 (ko) * 2003-07-26 2006-10-11 메덱스젠 주식회사 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
DK1874812T3 (da) * 2005-04-27 2013-12-09 Danisco Us Inc Fremgangsmåder til bestemmelse af proteasers allergenicitet
US20090222270A2 (en) * 2006-02-14 2009-09-03 Ivc Inc. Voice command interface device
SG170051A1 (en) * 2006-03-02 2011-04-29 Antitope Ltd T cell assays
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289689A (en) * 1980-03-14 1981-09-15 Hoffmann-La Roche Inc. Preparation of homogeneous human fibroblast interferon
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity

Also Published As

Publication number Publication date
US20090258832A1 (en) 2009-10-15
US20110263517A1 (en) 2011-10-27
US20050220800A1 (en) 2005-10-06
EP1578772A4 (en) 2007-05-09
WO2003104263A3 (en) 2005-12-08
EP1578772A2 (en) 2005-09-28
WO2003104263A2 (en) 2003-12-18
AU2003217758A1 (en) 2003-12-22
ATE467421T1 (de) 2010-05-15
DE60332556D1 (de) 2010-06-24
EP1578772B1 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
CY1119106T1 (el) Αντισωματα εναντι masp-2
DE60325892D1 (de) Stellungs- und verwendungsverfahren
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2006083301A3 (en) Immunogenic compositions comprising hmgb1 polypeptides
FR20C1016I1 (da)
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
DE60332842D1 (de) Antagonisten des nogo-rezeptors
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
HRP20050024A2 (en) Pegylated t20 polypeptide
CA2554195A1 (en) Peptide originating in epidermal growth factor receptor (egfr)
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
DE60331224D1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
WO2008054612A3 (en) Dna composition for eliciting an immune response against tumor-associated macrophages
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DK1290160T3 (da) Humane Pellino-polypeptider
WO2003093298A3 (en) Immunogenic peptides
DK1444356T3 (da) Identifikation af epitoper og mindskelse af allergeniciteten af fødevareproteiner
WO2003106650A3 (en) NUCLEIC ACIDS ENCODING CHD5, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
SG148195A1 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon